Stock Events

Stock Events

Medicenna Therapeutics 

$0.45
64
-$0.02-3.8% Thursday 19:17

Statistics

Day High
0.43
Day Low
0.43
52W High
1.43
52W Low
0.43
Volume
1,900
Avg. Volume
80,691
Mkt Cap
37.16M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25JunExpected
Q2 2024
Q3 2024
Q4 2024
Q2 2025
Q3 2025
Q4 2025
Next
-0.07
-0.06
-0.05
-0.05
Expected EPS
-0.06145533052200001
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-16.73MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MDNAF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is a leading biopharmaceutical company focusing on cancer therapies, directly competing with Medicenna's focus on oncology treatments.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a global healthcare company that develops cancer drugs, competing in the same therapeutic areas as Medicenna.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. specializes in antiviral drugs but has expanded into oncology, competing with Medicenna's cancer treatment research.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. is a biotech firm focusing on human therapeutics, including cancer treatments, making it a direct competitor.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. is a global pharmaceutical corporation with a broad portfolio that includes oncology, competing with Medicenna's cancer focus.
Novartis
NVS
Mkt Cap237.61B
Novartis AG is a healthcare company with a strong emphasis on research and development in oncology, directly competing with Medicenna.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG focuses on pharmaceuticals and diagnostics in oncology, making it a competitor in the cancer treatment market.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC is a biopharmaceutical company focusing on various therapeutic areas, including oncology, competing with Medicenna.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is known for its innovation in biotechnology, including cancer therapies, competing with Medicenna.
Incyte
INCY
Mkt Cap18.35B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, including oncology, making it a competitor.

About

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a tumor-targeting and activatable masked anti-PD-1-IL-2 BiSKITTM for cancer; and MDNA132, an IL-13 Superkine for various tumors. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Show more...
CEO
Dr. Fahar Merchant Ph.D.
Country
CA
ISIN
CA58490H1073

Listings

OTC Link
US
MDNAF
TO
CA
MDNA.TO

0 Comments

Share your thoughts

FAQ

What is Medicenna Therapeutics stock price today?▼
The current price of MDNAF is $0.45 USD — it has decreased by -3.8% in the past 24 hours. Watch Medicenna Therapeutics stock price performance more closely on the chart.
What is Medicenna Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Medicenna Therapeutics stocks are traded under the ticker MDNAF.
Is Medicenna Therapeutics stock price growing?▼
MDNAF stock has fallen by -3.17% compared to the previous week, the month change is a -30.82% fall, over the last year Medicenna Therapeutics has showed a -30.29% decrease.
What is Medicenna Therapeutics market cap?▼
Today Medicenna Therapeutics has the market capitalization of 37.16M
When is the next Medicenna Therapeutics earnings date?▼
Medicenna Therapeutics is going to release the next earnings report on June 25, 2026.
What were Medicenna Therapeutics earnings last quarter?▼
MDNAF earnings for the last quarter are -0.04 USD per share, whereas the estimation was -0.04 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Medicenna Therapeutics revenue for the last year?▼
Medicenna Therapeutics revenue for the last year amounts to 0 USD.
What is Medicenna Therapeutics net income for the last year?▼
MDNAF net income for the last year is -16.73M USD.
In which sector is Medicenna Therapeutics located?▼
Medicenna Therapeutics operates in the Health Care sector.
When did Medicenna Therapeutics complete a stock split?▼
Medicenna Therapeutics has not had any recent stock splits.
Where is Medicenna Therapeutics headquartered?▼
Medicenna Therapeutics is headquartered in Toronto, CA.